First Time Loading...
I

Intra-Cellular Therapies Inc
NASDAQ:ITCI

Watchlist Manager
Intra-Cellular Therapies Inc
NASDAQ:ITCI
Watchlist
Price: 70.34 USD -3.29%
Updated: May 3, 2024
Section:
 

Relative Value

The Relative Value of one ITCI stock under the Base Case scenario is 29.41 USD. Compared to the current market price of 70.34 USD, Intra-Cellular Therapies Inc is Overvalued by 58%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ITCI Relative Value
Base Case
29.41 USD
Overvaluation 58%
Relative Value
Price
I
Worst Case
Base Case
Best Case

Valuation Multiples

14.6
P/S
P/S
Price to Sales
14.6
vs History
76
vs Industry
12
Median 3Y
23.4
Median 5Y
35.3
Industry
2.4
Forward
10.1
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-17.1
Median 5Y
-14
Industry
22.9
Forward
-100.6
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-17.3
Median 5Y
-14.5
Industry
17.1
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-17.3
Median 5Y
-14.4
Industry
23.2
More Details
11.5
P/B
P/B
Price to Book Value
11.5
vs History
4
vs Industry
5
Median 3Y
7.7
Median 5Y
6.4
Industry
2.1
More Details
13.5
EV/S
EV/S
Enterprise Value to Sales
13.5
vs History
74
vs Industry
11
Median 3Y
20.1
Median 5Y
30.4
Industry
2.6
Forward
9.3
More Details
14.6
EV/GP
EV/GP
Enterprise Value to Gross Profit
14.6
vs History
69
vs Industry
13
Median 3Y
22
Median 5Y
22
Industry
5.1
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-14.8
Median 5Y
-12.1
Industry
13.6
Forward
-65.1
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-14.8
Median 5Y
-12.1
Industry
17
Forward
-70.5
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
Median 3Y
-15
Median 5Y
-12.2
Industry
15.8
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-15
Median 5Y
-12.2
Industry
17.6
More Details
28.7
EV/IC
EV/IC
Enterprise Value to IC
28.7
vs History
61
vs Industry
4
Median 3Y
31.4
Median 5Y
30.8
Industry
1.9
More Details

Multiples Across Competitors

ITCI Competitors Multiples
Intra-Cellular Therapies Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Intra-Cellular Therapies Inc
NASDAQ:ITCI
6.8B USD 14.6 -48.5 -39.5 -39.4
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
699.8B USD 20.4 133.3 60.3 69.3
DK
Novo Nordisk A/S
CSE:NOVO B
3.8T DKK 16.3 45.2 33 36
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
356.7B USD 4.4 8.8 11.7 15.5
US
Merck & Co Inc
NYSE:MRK
322.3B USD 5.2 139.7 33.3 52.8
UK
AstraZeneca PLC
LSE:AZN
186.4B GBP 5.1 39.2 140.6 225.6
CH
Novartis AG
SIX:NOVN
180.1B CHF 4.2 13.3 9.7 16.1
CH
Roche Holding AG
SIX:ROG
172.6B CHF 2.9 15 8.6 10.2
US
Pfizer Inc
NYSE:PFE
155.8B USD 2.7 73.5 11 16.2
P/E Multiple
Earnings Growth
US
I
Intra-Cellular Therapies Inc
NASDAQ:ITCI
Average P/E: 58.5
Negative Multiple: -48.5 		N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
133.3
346%
DK
Novo Nordisk A/S
CSE:NOVO B
45.2
84%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
US
Johnson & Johnson
NYSE:JNJ
8.8
-20%
US
Merck & Co Inc
NYSE:MRK
139.7
7 454%
UK
AstraZeneca PLC
LSE:AZN
39.2
168%
CH
Novartis AG
SIX:NOVN
13.3
15%
CH
Roche Holding AG
SIX:ROG
15
26%
US
Pfizer Inc
NYSE:PFE
73.5
680%

See Also

Summary
ITCI intrinsic value, competitors valuation, and company profile.
DCF Valuation
ITCI stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ITCI stock valuation using valuation multiples.
Wall Street Estimates
ITCI price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ITCI stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 133,800+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.